At a glance

Lipomedix is an early stage company developing a novel product, Promitil-Pegylated Liposomal Mitomycin C Prodrug (PL-MLP) – an innovative agent for targeted cancer therapy. Promitil® overcomes the tolerability issues associated with MMC toxicity, turning it into a state-of-the-art anti-cancer drug that will potentially become the therapy of choice in a variety of cancers, especially those derived from the gastrointestinal tract (stomach, pancreas, colorectal).